Bioton SA operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Bioton SA with three other
miscellaneous service companies in Europe:
sales of 60.62 million Swiss Francs [US$61.05 million]
of which 100%
was Discovering,Developing and Commercializi),
of the United Kingdom
(£54.11 million [US$66.72 million]
of which 51%
was Drug Safety and medical information serv), and
Circassia Pharmaceuticals PLC
based in the United Kingdom
(£48.30 million [US$59.56 million]
of which 57%
During the year ended December of 2018, sales at
Bioton SA were 241.17 million Polish New Zlotys (US$61.18 million).
decrease of 33.3%
versus 2017, when the company's sales were 361.65 million Polish New Zlotys.
Contributing to the drop in overall sales was the 99.8% decline
in Biolek, from 1.30 million Polish New Zlotys to 3,000.00 Polish New Zlotys.
There were also decreases in sales in
Insulin (Bioton Sa) (down 14.0% to 183.45 million Polish New Zlotys)
Scigen Group (down 60.7% to 57.72 million Polish New Zlotys)